SCOTUS' Mifepristone Decision Sets High Bar For US FDA Suits, But Risks To Agency Authority Linger

 
• By Sarah Karlin-Smith
female athlete performing high jump
The US Supreme Court abortion pill opinion sets a high bar for FDA lawsuits, but future tests of FDA's authority remain a risk. • Source: Shutterstock

More from Drug Safety

More from Pink Sheet